Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.48 |
| ▸ | ABAT | P80404 | 1/20 | 0.48 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.48 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30842561 | 0.89 | ALDH1A1 (0.47) | ALDH1A1TSHRTDP1TRIM24HPGD | |
| SCHEMBL30626955 | 0.87 | ALDH1A1 (0.46) | ALDH1A1TSHRTDP1TRIM24HPGD | |
| SCHEMBL31555989 | 0.87 | ALDH1A1 (0.46) | ALDH1A1TSHRTDP1TRIM24HPGD | |
| SCHEMBL29149139 | 0.87 | ALDH1A1 (0.46) | ALDH1A1TSHRTDP1TRIM24HPGD | |
| SCHEMBL11848099 | 0.84 | ALDH1A1 (0.50) | ALDH1A1TSHRTDP1TRIM24HPGD | |
| SCHEMBL28054406 | 0.81 | ALDH1A1 (0.47) | ALDH1A1TSHRTDP1TRIM24HPGD | |
| SCHEMBL17854886 | 0.80 | ALDH1A1 (0.46) | ALDH1A1TSHRTDP1TRIM24HPGD | |
| SCHEMBL29149114 | 0.80 | FDPS (0.40) | ALDH1A1TSHRTDP1TRIM24HPGD | |
| SCHEMBL4576166 | 0.79 | TRPA1 (0.48) | ALDH1A1TSHRTDP1TRIM24HPGD | |
| SCHEMBL14280291 | 0.76 | ALDH1A1 (0.38) | ALDH1A1TSHRTDP1TTRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119504367-A | Preparation method of benvimod | 承德医学院 | 2025-02-25 | — | — | CN | claimed |
| CN-115894186-B | Synthesis method of benvimod intermediate | 济川(上海)医学科技有限公司 | 2024-03-22 | — | — | CN | claimed |
| CN-115894186-A | Synthetic method of intermediate of limod | 济川(上海)医学科技有限公司 | 2023-04-04 | — | — | CN | claimed |
| CN-105884581-A | Method for preparing 2-(1-methylethyl)-5-[(E)-2-phenylethenyl]benzene-1,3-diol | 上海复星医药产业发展有限公司 | 2016-08-24 | — | — | CN | claimed |
| CN-122029153-A | Aromatic hydrocarbon receptor modulator compound, and preparation method and application thereof | 德明药泰生物技术（深圳）有限公司 | 2026-05-12 | — | — | CN | disclosed |
| WO-2025133100-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE PREPARATION OF TAPINAROF | INTERQUIM, S.A. (ES) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025099634-A1 | PROCESS FOR PREPARING THE POLYMORPHIC FORM III OF TAPINAROF | PROCOS S.P.A. (IT) | 2025-05-15 | — | — | WO | disclosed |
| WO-2025082312-A1 | AROMATIC HYDROCARBON RECEPTOR MODULATOR COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 德明药泰生物技术（深圳）有限公司 | 2025-04-24 | — | — | WO | disclosed |
| CN-119504367-A | Preparation method of benvimod | 承德医学院 | 2025-02-25 | — | — | CN | disclosed |
| CN-119504367-A | Preparation method of benvimod | 承德医学院 | 2025-02-25 | — | — | CN | disclosed |
| WO-2025008784-A1 | SOLID DISPERSIONS OF TAPINAROF AND A PROCESS FOR THE PREPARATION THEREOF | GLENMARK LIFE SCIENCES LIMITED (IN) | 2025-01-09 | — | — | WO | disclosed |
| CN-115894186-B | Synthesis method of benvimod intermediate | 济川(上海)医学科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-7321050-B2 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | WELICHEM BIOTECH INC. (CA) | 2008-01-22 | — | — | US | disclosed |
| CN-1319959-C | Hydroxystilbene, stilbene derivatives and analogues thereof for anti-inflammatory treatment of psoriasis and inhibition of protein kinase | CHEN GENHUI (CN) | 2007-06-06 | — | — | CN | disclosed |
| US-20050059733-A1 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | WELICHEM BIOTECH, INC. | 2005-03-17 | — | — | US | disclosed |
| US-20040102517-A1 | Modulators of T- cells, neutrophils, macrophages and their associated cytokines | GLAXO GROUP LIMITED (GB) | 2004-05-27 | — | — | US | disclosed |
| US-20030171429-A1 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxyltilbenes and novel stilbene derivatives and analogues | WELICHEMBIOTECH INC. (CA) | 2003-09-11 | — | — | US | disclosed |
| CN-1407978-A | Anti-inflammatory, psoriasis treatment and protein kinase inhibition using hydroxystilbenes, novel stilbene derivatives and analogues thereof | GENHUI CHEN (CA) | 2003-04-02 | — | — | CN | disclosed |
| EP-1248774-A2 | POLYHYDROXYSTILBENES AND STILBENE OXIDES AS ANTIPSORIATIC AGENTS AND PROTEIN KINASE INHIBITORS | Welichem Biotech Inc. (CA) | 2002-10-16 | — | — | EP | disclosed |
| WO-2001042231-A2 | POLYHYDROXYSTILBENES AND STILBENE OXIDES AS ANTISORIATIC AGENTS AND PROTEIN KINASE INHIBITORS | WELICHEM BIOTECH INC. (CA) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059733-A1 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | NFKBIA, IKBKB, IKBKE | ALDH1A1 3063/4885TSHR 3934/4885TDP1 2172/4885 |
| US-20040102517-A1 | Modulators of T- cells, neutrophils, macrophages and their associated cytokines | IL2, NFATC1, IFNG | ALDH1A1 2595/4885TSHR 1631/4885TDP1 1716/4885 |
| US-20030171429-A1 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxyltilbenes and novel stilbene derivatives and analogues | ROCK1, ROCK2, PTK2 | ALDH1A1 3304/4885TSHR 3614/4885TDP1 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.